Roche Pharma India recently introduce two innovative medicines for the treatment of HER2-positive metastatic breast cancer, a particularly aggressive form of the disease. The new drugs, Perjeta and Kadcyla, have been shown to both extend survival and improve quality of life in their approved applications for metastatic HER2-positive breast cancer.
Perjeta is approved in combination with trastuzumab (Herclon) and docetaxel chemotherapy for people with previously untreated HER2-positive metastatic breast disease (first-line treatment). Kadcyla is approved for people with HER2-positive metastatic breast disease previously treated with trastuzumab (Herclon) and taxane chemotherapy (second-line treatment).
With its targeted breast cancer medicine Herclon (globally known as Herceptin), Roche has helped transform the treatment of HER2-positive breast cancer over the last several years in India. Recognizing the need for additional treatment options, Roche is aiming to introduce a new standard of care for HER2-positive metastatic breast cancer patients in India with Kadcyla and Perjeta.
Perjeta is indicated for patients with previously untreated HER2-positive metastatic breast cancer. Kadcyla’s highly effective, targeted mode of action also offers patients a chance to extend their lives with fewer of the side effects commonly experienced with chemotherapy.
Subscribe to PharmaTutor News Alerts by Email >>
